Skip to main content

PORPHYRIA POST: Scenesse, FDA, and an EPP campaign update…

PORPHYRIA POST: Scenesse, FDA, and an EPP campaign update…

CLINUVEL PROVIDES UPDATE ON SCENESSE® FDA FILING

A company announcement from Clinuvel Pharmaceuticals was released on September 19, 2017 regarding their submission for approval to the FDA for the orphan drug SCENESSE® which is used to treat Erythropoietic Protoporphyria. The announcement discusses both regulatory status and post-marketing safety data. 

Clinuvel is seeking Priority Review for this product. This is a regulatory status that would decrease the review timeframe from the traditional 10 months to 6 months. The FDA response to this request is expected at the start of the review period. 

Clinuvel closely monitors the safety profile of SCENESSE® under a European Post Authorization Safety Study (PASS) protocol. Clinuvel has agreed with the FDA that safety data from PASS will form part of the US post-marketing submission.

Please read the following complete announcement from Clinuvel:

http://clinuvel.com/investors/news/item/5042-clinuvel-provides-update-on-scenesse-fda-filing


REMARKS FROM FDA COMMISSIONER DR. SCOTT GOTTLIEB
Dr. Scott Gottlieb, FDA Commissioner, spoke to the National Academy of Sciences yesterday on the impact of real world evidence on medical product development.  He outlined opportunities for the FDA to include real world evidence in product development and regulatory decision-making.  This is a positive sign that the FDA is looking outside of clinical data into the experience and voice of a patient.
During today’s workshop, and in the years ahead, I want you to know that FDA will support your work on these efforts. At FDA, we intend to expand our regulatory policy development work on achieving the more appropriate adoption of RWE (real world evidence) as part of the entire life cycle of medical products. We can’t do it alone. Your collaboration on these efforts is going to be critical to our success.”
You can read a complete transcript of the remarks here:
https://www.fda.gov/NewsEvents/Speeches/ucm576519.htm

EPP CAMPAIGN UPDATE
The APF will be launching another multi-faceted campaign seeking Scenesse approval. Stay tuned for further information and action alerts! It will take us all to participate to make this life-altering treatment available for ALL who seek it!

PATIENT MEETING – WASHINGTON, DC
Members in the Washington, DC area are invited to attend a Patient Education and Support Meeting at the home of Kristen Wheeden, the APF Director of Development in Bethesda, MD.  There will be a presentation and question/answer session with an on-site Porphyria expert.  Come meet old and new friends who share your experiences with Porphyria. Please RSVP to Edrin Williams in the APF office at 1.866.APF.3635 or edrinw@porphyriafoundation.org. We look forward to seeing you!



You are invited to an American Porphyria Foundation Patient Education and Support Meeting

Sunday Oct 22, 2017                  6:30PM-8:30PM EST

Question and Answer Session with a Porphyria Expert
Meet Old and New Friends who Share Tour Experiences with Porphyria
View the Latest Educational Material from the American Porphyria Foundation

At the Home of Kristen Wheeden
APF Director of Development
9007 Ewing Drive
Bethesda, MD 20817

Family and Friends are Welcome to Attend!

Please RSVP: 1.866.APF,3635 or Email: edrinw@porphyriafoundation.org


Comments

Popular posts from this blog

GLOBAL PORPHYRIA ALLIANCE

GLOBAL PORPHYRIA ALLIANCE The APF is proud to support our members that live across the globe. Many countries around the world have developed organizations to support their local communities. We hope that enjoy the same opportunity to communicate with one another, develop friendships, and learn about porphyria. Here are links to patient advocacy groups worldwide that offer support to individuals impacted by porphyria. Argentina: Centro de investigaciones sobre porfirinas y porfirias | More informationAustralia: Porphyria Association, Inc. | More informationBrazil: Associação Brasileira de Porfiria | More informationCanada: Canadian Association for Porphyria | More informationColombia: Fundación Colombiana Para La Porfiria | More informationDenmark: Porfyriforeningen.dk (Porphyria Association Denmark)Denmark: Porfyrier.dk (Danish Porphyria Support Group)England: British Porphyria AssociationFinland: Finnish Porphyria Support Group France: Association Française des Malades Atteints de Por…

WHAT IS NEUROPATHIC PAIN?

What could it be?
Nerve Pain WHAT IS NEUROPATHIC PAIN? Neuropathic or nerve pain (NP) is a long-term or chronic pain disease that results from nerve damage. It can be caused by different diseases or conditions. Worldwide nerve pain affects as many as 26 million people. Neuropathic or nerve pain may affect larger areas of the body or it can be restricted to a smaller area, in this case it is called localized neuropathic pain (LNP). WHAT CAUSES NEUROPATHIC PAIN? Neuropathic or nerve pain may occur in the absence of an obvious visible cause (e.g. an accident, an injury, a chemical burn). There are several external situations that can directly damage nerves and lead to neuropathic pain, such as: Amputation of a limb (phantom pain, stump pain)Surgery (scar pain, post-surgery pain)Trauma or accident Neuropathic pain is also a common complication of other diseases, including nerve damage after shingles or herpes zoster infection (postherpetic neuralgia or PHN), nerve damage after HIV infectio…

Happy Winter Season!

                  Happy Winter Season!